SCHEMBL7189092

SCHEMBL7189092

COc1cccc(OC)c1C(=O)Pc1ccc(OCC(C)C)cc1C.[LiH]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.39
FOS P01100 1/20 0.38
JUN P05412 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
MTNR1A P48039 3/20 0.37
MTNR1B P49286 3/20 0.37
FFAR1 O14842 2/20 0.36
PPARD Q03181 1/20 0.36
SLC16A3 O15427 2/20 0.36
SLC16A1 P53985 2/20 0.36
PDE4B Q07343 1/20 0.36
NR1H4 Q96RI1 2/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175607 0.94 MAPT (0.39) XDHFOSJUNSMN1; SMN2MAPT
SCHEMBL7179279 0.91 KMT2A (0.40) XDHFOSJUNSMN1; SMN2MAPT
SCHEMBL7187557 0.90 FOS (0.40) XDHFOSJUNSMN1; SMN2MAPT
SCHEMBL7183100 0.89 MAPK1 (0.40) SMN1; SMN2MAPTNR1H4CA12CA1
SCHEMBL7175998 0.88 XDH (0.39) XDHFOSJUNSIRT2MTNR1A
Lithium SCHEMBL7187564 0.87 MAPT (0.38) XDHFOSJUNSMN1; SMN2MAPT
SCHEMBL7187068 0.87 SMN1; SMN2 (0.49) SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL7176019 0.86 KMT2A (0.41) XDHFOSJUNSMN1; SMN2MAPT
SCHEMBL7183348 0.86 CA12 (0.39) SMN1; SMN2MAPTCA12CA1CA2
SCHEMBL7180005 0.85 MAPT (0.47) SMN1; SMN2MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 XDH 4277/4885FOS 2702/4885JUN 4136/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 XDH 4546/4885FOS 2549/4885JUN 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.